Form 8-K RIGEL PHARMACEUTICALS For: Apr 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Rigel Pharmaceuticals regains rights as Lilly terminates license deal
April 21, 2026 4:22 PM EDTRigel Pharmaceuticals Inc. (NASDAQ: RIGL) received notice that Eli Lilly and Company will terminate their license and collaboration agreement, effective June 15, 2026, according to a company statement.
Lilly notified Rigel on April 16, 2026 of its decision to terminate the February 2021 agreement in its entirety. The... More
